Evonik's Standalone Story Meets Its First Real Test

Evonik's board has drawn a line that stops short of a negotiating table. The chemicals group is willing to sit down with BASF for a confidential exchange of information — nothing more. That channel stays open, but it is not a mandate to discuss the offer, and it carries no hint of consent to it.

The distinction matters because the takeover fight is no longer only about price. BASF, according to Reuters, lifted its bid to EUR 24.00 per share on 23 October, valuing the deal at more than EUR 11 billion on the basis of media reports. Evonik has not confirmed that figure. The offer is understood to be all-cash, sweetened with commitments to preserve sites and jobs. Evonik shares closed Friday at EUR 21.06, leaving the stock below the bid on paper. That gap is not a locked-in return: without agreement, the offer price cannot be equated with a realisable sale proceeds.

A Rejection Built on More Than Money

Evonik turned down talks on the voluntary public takeover offer, citing a lack of industrial logic, according to Reuters. BASF met the refusal with incomprehension, pointing to its improved terms and its pledges on employees and locations. Those pledges, however, do not settle the question of how the combined company would be structured — and that question sits at the heart of the standoff.

Management has reaffirmed its focus on developing Evonik as an independent business. Syneqt, the subsidiary that bundles the chemical park operations in Marl and Wesseling, wants independence of its own. Its management spokesman came out in favour of that on Tuesday. The two positions are not the same thing: one concerns the group's future, the other a single division's. Neither amounts to a joint commitment to any particular transaction structure, though the difference is central to how investors should read any potential change.

Ashland Enters the Frame

Independence, in Evonik's telling, need not mean standing still. Reuters reported on 22 October, citing two insiders, that the group has been weighing a takeover of US specialty chemicals firm Ashland for months. The review is at an early stage and a deal is not certain; Evonik declined to comment. The Handelsblatt carried the same report the same day.

Should investors sell immediately? Or is it worth buying Evonik?

No value contribution can be inferred yet. Should a transaction take firmer shape, its economics and strategic rationale would have to convince. For shareholders, the signal would not be the acquisition itself but a coherent explanation of how it strengthens the standalone case. The report remains an unconfirmed possibility, not an announced purchase — and it follows neither a decision nor an executed deal.

What November 3 Can and Cannot Settle

The next hard datapoint is the quarterly statement for the third quarter of 2026, scheduled for 3 November. It gives investors their first concrete occasion to judge whether Evonik can back its independent path with numbers, and it may make the first of two separate questions — how the business is performing — easier to assess. The second, whether a deal with BASF can be reached, is not something a results release can answer.

A favourable scenario would see the statement furnish arguments for valuing Evonik without a takeover. Credible commentary on business development could make the standalone course economically traceable, and a well-grounded alternative to a merger might even strengthen Evonik's hand in any later talks. That is a scenario, not a confirmed outcome.

The counterargument is blunt: a rejected bid creates no corporate value by itself. If Evonik cannot substantiate its independent prospects, the gap between strategic ambition and economic justification persists, and references to possible acquisitions would not automatically close it. Nor should the confidential information exchange be over-read — no negotiations have been promised, and Reuters reports neither an agreement nor a further increase in the offer.

Two Paths, Neither Yet Paved

Investors therefore face a pair of open decisions rather than a settled outcome. Ashland's early review stage permits no reliable conclusion about completion, and the BASF situation depends on moves yet to be made. Neither should be treated as a fixed input to valuation.

So long as Evonik can make its standalone development plausible, the refusal to negotiate remains strategically explicable. Weaken that case, and the economic merits of BASF's offer move to the foreground. A convincing business performance, conversely, could reduce the weight takeover speculation carries in the share price. The benchmark for shareholders extends beyond the bid: Evonik has to show why going it alone is a credible alternative.

Ad

Evonik Stock: New Analysis - 1 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...